[ad_1]
Lisa Anson of Redx Pharma PLC (LON: REDX), addresses Andrew Scott of Proactive London after announcing the sale of one of their cancer research programs at a price that can reach 203 million US dollars.
The agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ) in the United States has a tiered payment structure and Redx will receive an initial sum of 3.5 million US dollars.
Source link
